Search

Author/Creator Kater, Arnon P

1. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Issue 10121 (17th February 2018)

Authors:
Wang, Michael; Rule, Simon; Zinzani, Pier Luigi; Goy, Andre; Casasnovas, Olivier; Smith, Stephen D; Damaj, Gandhi; Doorduijn, Jeanette; Lamy, Thierry; Morschhauser, Franck; Panizo, Carlos; Shah, Bijal; Davies, Andrew; Eek, Richard; Dupuis, Jehan; Jacobsen, Eric; Kater, Arnon P; Le Gouill, Steven;...
Journal:
Lancet
Issue:
Volume 391:Issue 10121(2018)
Page Start:
659
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells. Issue 1 (24th June 2020)

Authors:
Martens, Anne W J; Janssen, Susanne R; Derks, Ingrid A M; Adams III, Homer C; Izhak, Liat; van Kampen, Roel; Tonino, Sanne H; Eldering, Eric; van der Windt, Gerritje J W; Kater, Arnon P
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8:Issue 1(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled Trial. (4th August 2022)

Authors:
Huygens, Sammy; Hofsink, Quincy; Nijhof, Inger S; Goorhuis, Abraham; Kater, Arnon P; te Boekhorst, Peter A W; Swaneveld, Francis; Novotný, Věra M J; Bogers, Susanne; Welkers, Matthijs R A; Papageorgiou, Grigorios; Rijnders, Bart J; Heijmans, Jarom
Journal:
Journal of infectious diseases
Issue:
Volume 227:Number 2(2023)
Page Start:
206
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Issue 10 (October 2017)

Authors:
Fink, Anna Maria; Bahlo, Jasmin; Robrecht, Sandra; Al-Sawaf, Othman; Aldaoud, Ali; Hebart, Holger; Jentsch-Ullrich, Kathleen; Dörfel, Steffen; Fischer, Kirsten; Wendtner, Clemens-Martin; Nösslinger, Thomas; Ghia, Paolo; Bosch, Francesc; Kater, Arnon P; Döhner, Hartmut; Kneba, Michael; Kreuzer, Ka...
Journal:
Lancet
Issue:
Volume 4:Issue 10(2017)
Page Start:
e475
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial. Issue 6 (June 2022)

Authors:
Kater, Arnon P; Levin, Mark-David; Dubois, Julie; Kersting, Sabina; Enggaard, Lisbeth; Veldhuis, Gerrit J; Mous, Rogier; Mellink, Clemens H M; van der Kevie-Kersemaekers, Anne-Marie F; Dobber, Johan A; Poulsen, Christian B; Frederiksen, Henrik; Janssens, Ann; Schjødt, Ida; Dompeling, Ellen C; Ran...
Journal:
Lancet oncology
Issue:
Volume 23:Issue 6(2022)
Page Start:
818
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial. Issue 3 (March 2022)

Authors:
Kersting, Sabina; Dubois, Julie; Nasserinejad, Kazem; Dobber, Johan A; Mellink, Clemens; van der Kevie-Kersemaekers, Anne-Marie F; Evers, Ludo M; de Boer, Fransien; Koene, Harry R; Schreurs, John; van der Klift, Marjolein; Velders, Gerjo A; van der Spek, Ellen; van der Straaten, Hanneke M; Hoogen...
Journal:
Lancet
Issue:
Volume 9:Issue 3(2022)
Page Start:
e190
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. Issue 4 (April 2018)

Authors:
Brown, Jennifer R; Hamadani, Mehdi; Hayslip, John; Janssens, Ann; Wagner-Johnston, Nina; Ottmann, Oliver; Arnason, Jon; Tilly, Hervé; Millenson, Michael; Offner, Fritz; Gabrail, Nashat Y; Ganguly, Siddhartha; Ailawadh, Sikander; Kasar, Siddha; Kater, Arnon P; Doorduijn, Jeanette K; Gao, Lei; Lage...
Journal:
Lancet
Issue:
Volume 5:Issue 4(2018)
Page Start:
e170
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. Issue 4 (April 2018)

Authors:
Brown, Jennifer R; Hamadani, Mehdi; Hayslip, John; Janssens, Ann; Wagner-Johnston, Nina; Ottmann, Oliver; Arnason, Jon; Tilly, Hervé; Millenson, Michael; Offner, Fritz; Gabrail, Nashat Y; Ganguly, Siddhartha; Ailawadhi, Sikander; Kasar, Siddha; Kater, Arnon P; Doorduijn, Jeanette K; Gao, Lei; Lag...
Journal:
Lancet
Issue:
Volume 5:Issue 4(2018)
Page Start:
e170
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗